Vertanical's cannabis drug effective for chronic back pain

A new cannabis-derived painkiller from Germany's Vertanical has shown promising results in clinical trials for treating chronic back pain. This drug, called VER-01, could provide a safer alternative to traditional opioid medications. In phase 3 trials, VER-01 demonstrated effectiveness in reducing chronic lower back pain. Over 820 participants were involved in placebo-controlled studies. The results indicate that the treatment did not lead to serious side effects or any potential for addiction. Vertanical has shared data from the trials and is working on getting its drug approved in Germany and Austria, with a decision expected in July. If approved, it will be marketed under the name Exilby. Dr. Clemens Fischer, CEO of Vertanical, emphasized that many pain patients struggle with related issues like insomnia and limited mobility. He believes VER-01 could help break this cycle. The development is significant as it comes amid a growing need for alternatives to opioids. The opioid crisis has led to increased addiction and overdose deaths in several countries, including the United States. According to Vertanical, over 1.5 billion people globally suffer from chronic pain, making it more common than several major diseases combined. They noted that current opioids only give long-term relief to about 30% of patients. Dr. Philipp Müller-Schwefe, involved in the study, called VER-01 a potentially safer and more effective option for those struggling with chronic back pain. He sees it as a revolutionary advancement in pain management. Looking ahead, Vertanical plans to apply for approval in other countries, including the EU, UK, and USA, and will also begin more clinical trials for additional pain types. If successful, it will be the first cannabinoid-based treatment specifically for chronic lower back pain.